Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ORY.MCthis companyOryzon Genomics S.A.	€2.36	-88.86×	2.19×	0×	-34.19×	-90.8%	0.0%	0.0%	0.0%	-2.5%	-2.2%	-1.0%	0.11×	2.61×	-10.55×	1.95×	0.0%	2	5.2	2	C+
ATRY.MCAtrys Health, S.A.	€2.65	-2.22×	1.47×	1.58×	-46.9×	-255.2%	43.5%	-6.4%	-71.1%	-66.0%	-2.1%	-6.3%	1.7×	-24.57×	-0.47×	0.81×	0.0%	3	-0.45	1	C-
BST.MCBiotechnologies Assets S.A.	€0.20	-7.42×	2.31×	4.61×	138.37×	-110.4%	-16.6%	-61.6%	-62.0%	-31.0%	-16.8%	-0.1%	0.28×	11.74×	-11.17×	1.4×	0.0%	4	-1.34	1	C-
CBAV.MCClínica Baviera, S.A.	€51.40	18.9×	7.52×	2.74×	8.39×	-33.0%	42.1%	27.3%	13.9%	38.2%	29.5%	5.6%	0.63×	0.6×	36.05×	0.96×	3.2%	5	5.81	4	A-
PANG.MCPangaea Oncology, S.A.	€1.47	-15.73×	2.77×	4.07×	-66.52×	-931.0%	99.3%	-25.1%	-24.8%	-16.9%	-11.3%	-5.1%	0.27×	-4.07×	-12.2×	1.78×	0.0%	2	2.65	1	C-
PRM.MCPrim, S.A.	€12.35	13.47×	163.15×	89.18×	661.57×	-98.1%	50.4%	8.9%	6.6%	12.1%	10.8%	0.1%	0.12×	-0.06×	41.78×	2.99×	0.0%	8	3.8	3	B+
Peer median	—	-2.22×	2.77×	4.07×	8.39×	-110.4%	43.5%	-6.4%	-24.8%	-16.9%	-2.1%	-0.1%	0.28×	-0.06×	-0.47×	1.4×	0.0%	4	2.65	1	—